Loading…
Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): Effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients
Background: Previous evidence indicates that pioglitazone may improve dyslipidemia in patients with Type 2 diabetes mellitus (T2DM). Aim: The primary objective of this study was to evaluate the effect of either pioglitazone or placebo with metformin on levels of serum HDL cholesterol (HDL-C) in pati...
Saved in:
Published in: | Journal of endocrinological investigation 2013-09, Vol.36 (8), p.606-616 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background:
Previous evidence indicates that pioglitazone may improve dyslipidemia in patients with Type 2 diabetes mellitus (T2DM).
Aim:
The primary objective of this study was to evaluate the effect of either pioglitazone or placebo with metformin on levels of serum HDL cholesterol (HDL-C) in patients with T2DM. A secondary objective evaluated changes in metabolic syndrome (MS)-specific parameters.
Subjects and Methods:
This multicenter, double-blind, randomized study was performed in patients with T2DM treated with metformin and hemoglobin A1c (HbA
1c
) levels between 6–8%, central obesity and reduced HDL-C. MS was evaluated from global changes in parameter values and expressed as a single factorial score following multivariate analysis of each parameter. 213 patients (110 in the pioglitazone group and 103 in the placebo group) were available for intention-to-treat analysis.
Results:
Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6.3 mg/dl
vs
3.0 mg/dl;
p |
---|---|
ISSN: | 0391-4097 1720-8386 |
DOI: | 10.3275/8895 |